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Abstract
Background: TGF-β resistance often develops in breast cancer cells that in turn overproduce this
cytokine to create a local immunosuppressive environment that fosters tumor growth and
exacerbates the invasive and metastatic behavior of the tumor cells themselves. Smads-mediated
cross-talk with the estrogen receptor has been implied to play an important role in development
and/or progression of breast cancer. We investigated how TGF-β regulates ERα-induced gene
transcription and potential mechanisms of frequent TGF-β resistance in breast cancer.
Methods: Effect of TGF-β on ERα-mediated gene transcription was investigated in breast cancer
cell lines using transient transfection, real-time PCR, sequential DNA precipitation, and small
interfering RNA assays. The expression of Smads on both human breast cancer cell lines and ERα-
positive human breast cancer tissue was evaluated by immunofluorescence and
immunohistochemical assays.
Results: A complex of Smad3/4 mediates TGF-β inhibition of ERα-mediated estrogenic activity of
gene transcription in breast cancer cells, and Smad4 is essential and sufficient for such repression.
Either overexpression of Smad3 or inhibition of Smad4 leads to the "switch" of TGF-β from a
repressor to an activator. Down-regulation and abnormal cellular distribution of Smad4 were
associated with some ERα-positive infiltrating human breast carcinoma. There appears a dynamic
change of Smad4 expression from benign breast ductal tissue to infiltrating ductal carcinoma.
Conclusion: These results suggest that aberrant expression of Smad4 or disruption of Smad4
activity lead to the loss of TGF-β suppression of ERα transactivity in breast cancer cells.
Background
Estrogens act as mitogens to promote cell proliferation in
both normal breast tissue and breast carcinomas through
their binding to estrogen receptors (ER). The ERα is a tran-
scriptional activator and regulates gene transcription
either by directly binding to the estrogen-responsive ele-
ment (ERE) or by interacting with other transcription fac-
tors [1,2]. Gene amplification or overexpression of ERα
was found in some breast cancer [3,4]. Approximately
70% of breast cancers are ERα positive and estrogen
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dependent. ERα has become an important prognostic
marker and a therapeutic target in breast cancer [5,6].
In contrast to estrogens, which induce proliferation of
breast cancer cells, transforming growth factor-β (TGF-β)
inhibits the growth of human breast cancer cells in culture
[7,8]. TGF-β is the prototypic inhibitor of cell cycle pro-
gression and appears to directly antagonize the effects of
many different mitogenic growth factors. A well-character-
ized TGF-β signaling pathway is initiated by the associa-
tion between TGF-β and its two cell surface receptors,
resulting in the formation of the receptor heterocomplex
and activation of the type I receptor, which in turn acti-
vates the cytoplasmic receptor regulated-Smad (R-Smad:
Smad2 and Smad3) proteins via phosphorylation [9].
Phosphorylated R-Smad associates with Smad4. The
resulting heteromeric Smad complexes then translocate
into the nucleus, where they regulate gene transcription in
collaboration with other factors. The importance of the
TGF-β signaling pathway in cancer development is under-
scored by the presence of downregulation or inactivating
mutations in genes encoding TGF-β receptors and Smads
in human carcinomas [10-12].
While the role of TGF-β in breast cancer is ambiguous, as
it was shown to display both tumor-suppressing and -
enhancing effects, loss of responsiveness to TGF-β is
believed to be a major factor in tumor formation [13-15].
Activation of TGF-β represents one of the physiological
countermeasures that are invoked to protect transformed
cells against ERα excessive mitogenic stimulation. Addi-
tionally, inhibition of some breast cancer cell growth by
tamoxifen appears to be mediated by TGF-β signaling
pathway [16]. Inhibition of Tβ RII expression abolished
antiestrogen-dependent growth inhibition [17,18]. It has
been shown that Smad2, Smad3 and Smad4 all have
physical interactions with ERα and that Smad4 acts as a
transcriptional co-repressor for ERα and inhibits tumor
growth by inducing apoptosis in ERα-positive cells [19-
22]. Although the regulated gene targets of Smads/ERα
have not been identified, these findings imply that Smads-
mediated cross-talk with the estrogen receptor plays an
important role in development and/or progression of
breast cancer.
In this study, we investigated how TGF-β regulates ERα-
induced gene transcription and potential mechanisms of
frequent TGF-β resistance in breast cancer. We demon-
strated that Smad4 is essential for TGF-β-mediated inhibi-
tion of ERα estrogenic transcription activity. Either
overexpression of Smad3 or inhibition of Smad4 expres-
sion switches TGF-β to an activator for ERα transactiva-
tion in breast cancer cells. In addition, we found that the
expression of Smad4 was downregulated with increased
cytoplasmic localization in ERα-positive human infiltrat-
ing breast cancer tissue.
Methods
Cell Culture, Transient Transfection and Reporter Assays
MCF-7 cells were purchased from the American Type Cul-
ture Collection and maintained according to the manufac-
turer's instructions. MDA-MB-231 and MDA-MB-468 cells
were a gift from Dr. Joseph Messina (Department of
Pathology, University of Alabama at Birmingham, Bir-
mingham, AL). These two cell lines were incubated in Lei-
bovitz's L-15 medium with 2 mM L-glutamine (ATCC)
supplemented with antibiotics and 10% fetal bovine
serum (Cellgro) at 37°C in 5% CO2. COS-1 cells were
incubated in Dulbecco's modified Eagle's medium (Cell-
gro) supplemented with antibiotics and 10% fetal bovine
serum at 37% in 5% CO2. The methods used for transient
transfection and luciferase assay have been described in
Wu L. et al. [21]. Similarly, 2× ERE-TATA reporter plasmid
was used to examine the function of TGF-β/Smads on the
estrogen response element. The breast cancer cell line
(MCF-7, MDA-MB-231 or MDA-MB-468) cells were split
and plated at 5 × 104 cells/24-well plate. The cells were
starved with Dulbecco's modified Eagle's phenol red-free
medium supplemented with 10% charcoal-stripped
bovine serum (Cellgro) for 24 hours. Transient transfec-
tions were performed using LipofectAMINE plus reagent
(Invitrogen) with 0.2 μg of luciferase reporter and 2-20 ng
(2 ng for MCF-7 cells; 20 ng for MDA-MB-231/468 cells)
of the hERα expression plasmid. The amount of co-trans-
fected Smad expression plasmid is indicated in the figures
and text. Aliquots of cells were treated with E2, 1 nM
(Sigma), TGF-β1, 100 pM (R&D), or a combination of E2
+ TGF-β1. Sixteen hours after the treatment, luciferase
activity was assayed in each cell line using the Dual-luci-
ferase™ assay kit (Promega) according to the manufac-
turer's instructions.
Plasmids
HA-tagged human ERα plasmid was cloned into a
pCDNA3 vector as described in previous studies [21]. The
expression vectors pFLAG-Smad2, pFLAG-Smad3 and
pFLAG-Smad4 were gifts from Dr. Rik Derynck (Univer-
sity of California at San Francisco, San Francisco, CA). The
2× ERE-TATA reporter was a gift from Dr. Valerie Clark
(Duke University Medical Center, Durham, NC).
Semi Quantitative Real Time PCR
The target cDNA sequence was evaluated using Primer3
http://frodo.wi.mit.edu/primer3. The sequences of prim-
ers used in RT-PCR assays are listed as follows: β-actin
upper primer, 5'-AGACTTCGAGCAGGAGCTGG-3'; β-
actin lower primer, 5'-CGGATGTCAACGTCACACTT-3';
PS2 upper primer, 5'-TTGTGGTTTTCCTGGTGTCA-3'; PS2
lower primer, 5'-CCGAGCTCTGGGACTAATCA-3'; C-
MYC upper primer, 5'-CTCCTGGCAAAAGGTCAGAG-3';
C-MYC lower primer, 5'-TCGGTTGTTGCTGATCTGTC-3'.
Total RNA was extracted from each breast cancer cell line
using STAT-60 (TEL-TEST Inc.). The detailed proceduresMolecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
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for mRNA purification, reverse transcription and semi
quantitative real time PCR have been described previously
[21].
Co-immunoprecipitation and Immunoblotting assays
To detect endogenous-endogenous, endogenous-exoge-
nous or exogenous-exogenous protein complexes, breast
cancer cells or COS-1 cells were transfected with expres-
sion plasmid(s) encoding the indicated proteins or left
untransfected. Thirty-six hours post-transfection, aliquots
of cells were incubated for 1 hr in the presence or absence
of β-estradiol (E2) and/or TGF-β1. Cells were lysed with
radioimmune precipitation assay buffer [21], precleared
with purified mouse or rabbit IgG [23], and centrifuged at
13,000 × g for 30 mins. Supernatants were incubated with
antibodies and protein A/G beads for 3 hr at 4°C on a
rotating platform. Immunoprecipitates were separated by
7%-12% SDS-PAGE and transferred to PVDF membranes
(BioRad). Immunoblotting was carried out as previously
described [21]. The antibodies used for immunoprecipita-
tion and immunoblotting are listed as follows: anti-FLAG
M2 (F3165, Sigma), anti-HA (rabbit polyclonal, H9658,
Sigma), anti-Smad2/3 [23], anti-Smad4 (sc-7154, and sc-
7966, Santa Cruz), and anti-ERα (sc-8002, Santa Cruz).
Immunofluorescence Detection
The procedure for immunofluorescence staining was adapted
from the online protocol http://www.bdbiosciences.com/
pharmingen/protocols/Immunofluorescence Microscopy.
shtml of BD Biosciences: Pharmingen: Protocols. The primary
antibodies used were: monoclonal mouse anti-Smad2/3
(S66220, BD Transduction Laboratories) and polyclonal rab-
bit anti-Smad4 (sc-7154, Santa Cruz). The secondary Texas-
red™-conjugated goat anti-rabbit and FITC-conjugated goat
anti-mouse antibodies were used for immunofluorescence
detection. The DNA dye 4',6-diamidino-2-phenylindole,
dihydrochloride (DAPI) (D21490, "FluoroPureTM" grade,
Molecular Probes) was used after the secondary antibodies to
visualize the nucleus of the cells. Images were captured with an
Olympus IX70 inverted fluorescence microscope and Mag-
naFire SP (Optronics) digital camera and visualized using
Adobe Photoshop 7.0 and Image-pro® Express 4.5 (MediaCy-
bernetics Inc.) software.
Immunohistochemical Assay
Immunohistochemical staining was performed on serial
paraffin-embedded sections of human breast tissue using
UltraVision One detection system (HRP polymer & DAB
Plus chromogen, Thermo Fisher Scientific, Fremont, CA).
The mouse monoclonal antibody against Smad4 was used
at a dilution of 1:250. Sections of 4 μm were deparaffin-
ized and boiled in Tris-EDTA buffer (10 mM Tris Base, 1
mM EDTA solution, 0.05% Tween 20, pH9.0) for 15 min-
utes. They were incubated with Ultra V Block for 5 min to
block nonspecific binding. The sections were then incu-
bated overnight with anti-Smad4 antibody at 4°C. After
washing in TBS 0.025% Triton X-100, the slides were incu-
bated in Hydrogen Peroxide Block for 10 minutes. After
washing in TBS buffer, they were incubated with UltraVi-
son One HRP Polymer (second antibodies) for 30 min-
utes, followed by staining with DAB Plus Chromogen and
Substrate. Counterstaining was performed with hematox-
ylin.
Sequential DNA Precipitation Assay
To study the ERα-associated ERE complex, COS-1 cells
were co-transfected with HA-tagged ERα, FLAG-tagged
Smad3 and FLAG-tagged Smad4. The ERα-containing pro-
tein complexes were first immunoprecipitated with an
anti-HA antibody and eluted with HA-tagged peptide
(I2149, Sigma). The eluates were then subjected to DNA
precipitation assays as described by Chen et al [23] and
Bonni et al [24]. The sequences of biotin-labeled wild-
type and mutant ERE oligonucleotides are listed as fol-
lows: Biotin-ERE (forward): 5'-GATCTCGAGTCAGGT-
CACAGTGACCTGA-3'; Biotin-ERE (reverse): 5'-TCAGGT
CACTGTGACCTGACTCGAGATC-3'; Biotin-mutantERE
(forward): 5'-GATCTCGAGTCACCGCACAGTGAAATGA-
3'; Biotin-mutantERE (reverse): 5'-TCATTTCACTGTGCG-
GTGACTCGAGATC-3'. Finally, the precipitated protein
complexes which contain ERE-bound ERα were examined
by immunoblotting assays with an anti-FLAG antibody.
Small Interfering RNA (siRNA)
siRNA targeting Smad4 was prepared by cloning between
the ApaI and EcoRI site of the Multi Cloning Sites of the
pBS/U6 vector. The specific sequence for Smad4 was
determined with assistance from siRNA Target Finder
(Ambion®, Inc.). DNA oligonucleotides with the follow-
ing sequences, along with their complementary strands,
were synthesized by Operon (QIAGEN): siRNA for
Smad4:
Forward: 5'-CATTGGATGGGAGGCTTCATTCAAGCTTT-
GAAGCCTCCCATCCAA TGTTTTTT-3'; Reverse: 5'-
AATTAAAAAACATTGGATGGGAGGCTTCAAAGCTT GAA
TGAAGCCTCCCATCCAATGGGCC-3'. Similar oligonu-
cleotides with the following scrambled sequences were
designed as negative controls:
Forward: 5'-TAGTCTAGGAGGTCGAGTCTTCAAGCTT-
GACTGACCTCCTAGACT ATTTTTT-3'; Reverse: 5'-
AATTAAAAAATAGTCTAGGAGGTCGAGTCAAGCTTG AA
GACTCGACCTCCTAGACTAGGCC-3'. Each pair of DNA
oligos was annealed and cloned into the pBS/U6 vector
between ApaI and EcoRI site. MCF-7 cells were transfected
with siRNA using LipofectAMINE plus reagent. Sixty
hours after transfection, cells were treated with or withoutMolecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
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E2 and/or TGF-β for 8 hours. Total RNA and cell lysates
were prepared and subjected to RT-PCR or western blot-
ting analysis respectively.
Results
The Smad3/4 Complex Confers TGF-β Repression of ERα-
Mediated Gene Transcription
The complex of R-Smads and Smad4 forms the core of
transcriptional regulatory machinery in TGF-β signaling.
We have demonstrated that the expression of Smad4 with-
out TGF-β treatment inhibited ERα-mediated transcrip-
tion in a dose-dependent manner [21]. Both Smad3 and
Smad2 were shown to interact with ERα, thereby having a
direct impact on both TGF-β and estrogen signaling path-
ways [19,21,22]. We therefore examined how the com-
plexes of Smad4 and R-Smads mediate estrogen signal
transduction through their interactions with ERα in breast
cancer cells. We first performed a reporter assay using a
construct bearing two repeats of the estrogen response ele-
ment (ERE) and luciferase cDNA (2× ERE-TATA-LUC).
MCF-7 breast cancer cells were co-transfected with expres-
sion plasmids of Smad2, Smad3, Smad4, or Smad4 in
combination with either Smad2 or Smad3. The cells were
then treated for 16 hours with either β-estradiol (E2) alone
or E2 in combination with TGF-β1. As shown in Figure 1a,
expression of either Smad2 or Smad3 enhanced E2-
induced luciferase transcription in a dose-dependent
manner. Smad2 had a limited effect. Overexpression of
Smad4 alone or with Smad3 strongly attenuated E2-
induced luciferase activity, whereas Smad2/4 only
showed moderate inhibition. These results clearly indi-
cate that Smad3 and Smad4 act as ERα coactivator and
The Smad3/4 complex confers TGF-β repression on ERα-mediated transcription Figure 1
The Smad3/4 complex confers TGF-β repression on ERα-mediated transcription. Smads (Smad2, Smad3, and 
Smad4 alone or combinations of Smad2/4 or Smad3/4) or empty vector was co-transfected into MCF-7 cells (a) or MDA-MB-
468 cells (b). The cells were treated with (+) or without (-) E2 and/or TGF-β as indicated for 16 hours prior to lysis, and ana-
lyzed for luciferase activity. (c-d) MCF-7 cells were transfected with Smad2/4 or Smad3/4 and treated with (+) or without (-) E2 
and/or TGF-β as indicated for 8 hours. Total mRNA was isolated and the mRNA levels of PS2 and C-MYC were detected and 
quantified by reverse transcription and semi-quantitative real time PCR.Molecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
Page 5 of 11
(page number not for citation purposes)
corepressor, respectively, and that Smad4 overrides
Smad3/4 in the repression of ERα-induced transcription.
Apparently, Smad2 is not a potent ERα coactivator, nor is
the Smad2/4 complex an effective repressor. To confirm
this observation, we performed a similar experiment in
the breast cancer cell line MDA-MB-468 which lacks
endogenous ERα and Smad4 [25]. By transient expression
of a small amount of ERα, we reconstituted ERα-mediated
signaling. Overexpression of Smad3 enhanced ERα-
induced transcription, while Smad4 alone or in complex
with Smad3 inhibited ERα transcription activity (Figure
1b). These results are similar to those observed in MCF-7
cells.
ERα regulates gene transcription either by binding directly
to the promoter of target genes (such as PS2) or by bind-
ing indirectly through a mechanism involving other tran-
scription factors such as Sp1 and AP1 (such as C-MYC). To
determine whether Smad4 and R-Smads also regulate ERα
downstream genes, we measured the endogenous mRNA
levels of PS2  and  C-MYC, using endogenous β-actin
mRNA as a control. The MCF-7 hormone-dependent
breast cancer cell line was transiently transfected with
Smad2/4 or Smad3/4 and treated with TGF-β1 for 8
hours. Total mRNA was extracted followed by reverse
transcription and semi-quantitative real time PCR. As
shown in Figures 1c and 1d, TGF-β downregulated the
expression levels of PS2 and C-MYC mRNA stimulated by
E2. Transient expression of Smad3/4 repressed the tran-
scription of these two genes, while overexpression of
Smad2/4 did not significantly alter the transcriptional
activity. These results clearly indicate that, in breast cancer
cell lines, Smad4 can either function as an ERα transcrip-
tional co-repressor on its own or mediate TGF-β suppres-
sion by forming a complex with Smad3.
Smad4 Is Essential For TGF-β-Mediated Repression of ERα 
Transactivation
Our next objective was to investigate how Smad3 and
Smad4 can act differently in regulating ERα transcrip-
tional activity. Smad3 is known to form a complex with
Smad4 and translocate into the nucleus upon TGF-β-
induced phosphorylation. Similarly, the estrogen recep-
tor, upon binding an estrogenic ligand such as E2, dimer-
izes and translocates into the nucleus. Therefore, we
employed a co-immunoprecipitation (co-IP) assay to
determine whether TGF-β and E2 can regulate the interac-
tion of ERα with Smad3 and Smad4. MCF-7 breast cancer
cells were treated with either E2 alone or E2 together with
TGF-β1. The whole cell lysates were subjected to co-IP
assays using anti-Smad4 or anti-Smad2/3 antibodies. The
results demonstrated that the interaction between Smad2/
3 and ERα was enhanced within 1 hr of TGF-β addition,
while Smad4 binding ERα was not dependent upon either
E2 or TGF-β1 stimulation (Figure 2a). Immunoprecipita-
tion with a control mouse or rabbit IgG revealed no
detected product (data not shown). The canonical tran-
scriptional activation of ER target genes is attributable to
the direct binding of ER to the estrogen responsive ele-
ment in the promoter region of ER target genes. In our pre-
vious studies with chromatin immunoprecipitation assay
[21], we demonstrated the Smad4 expression did not
inhibit ERα binding to the chromatin. To further examine
if Smad3/Smad4/ERα complex can bind to the ERE, we
performed a sequential DNA precipitation assay [23].
FLAG-tagged Smad3 and Smad4 were co-transfected into
COS-1 cells with HA-tagged ERα expression plasmids. The
cells were then treated with E2, TGF-β or E2 + TGF-β. HA-
tagged ERα was precipitated from cell extracts with anti-
HA antibody. The precipitates were eluted with an HA
peptide and subjected to DNA precipitation (DNAP) with
either biotinylated ERE double-stranded DNA oligonucle-
otides (wild-type) or a disrupted sequence (mutant) as a
control for the experiment. The precipitated protein com-
plexes were examined by anti-FLAG, anti-HA, and control
IgG antibodies. As shown in Figure 2b, the wild-type ERE
probe precipitated ERα, Smad4 and a noticeable amount
of Smad3. Immunoblotting with a control IgG revealed
no detected bands. A treatment with TGF-β1 enhanced the
association of Smad3, but not that of Smad4, with the
ERα-containing ERE precipitates (Figure 2b), that are con-
sistent with the co-IP assay results (Figure 2a). These data
suggest that Smad4 can function as an ERα corepressor
independent of TGF-β signaling, whereas Smad3 acts as a
TGF-β-regulated cofactor for ERα.
We previously demonstrated that Smad4 through its MH1
domain and linker region interacted with the activation
function 1 domain of ERα and that the ectopic expression
of Smad4 inhibited E2- induced luciferase activity in a
dose-dependent manner [21]. In addition, in breast T47D
cells with undetected Smad4, ectopic expression of Smad4
resulted in inhibition of endogenous ERα direct response
genes [21]. To further examine the essential role of Smad4
in the cross-talk between TGF-β and estrogen signaling,
we reduced the expression level of endogenous Smad4
using a small interfering RNA (siRNA) gene silencing tech-
nique. As shown in Figure 3a, Smad4 protein was almost
non-detectable in the MCF-7 cells treated with Smad4-
specific siRNA (siRNA-Smad4), while treatment of the
MCF-7 cells with a non-specific siRNA (siRNA-Control)
did not change the protein level of Smad4 or other control
genes. The effect of TGF-β on ERα-induced transcription
was measured on two ERα downstream genes PS2 and C-
MYC. As expected, transcription of both genes in the con-
trol cells (treated with siRNA-Control) was up-regulated
by E2 treatment and down-regulated by TGF-β (Figure 3b).
In the siRNA-Smad4 treated cells, however, E2 induction
enhanced the expression of both PS2 and C-MYC genes.
Moreover, the addition of TGF-β did not result in repres-Molecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
Page 6 of 11
(page number not for citation purposes)
The EREaccommodates Smad3/4 and ERα complexes in the nucleus Figure 2
The EREaccommodates Smad3/4 and ERα complexes in the nucleus. (a) MCF-7 cells were treated with E2, E2 + TGF-
β1 or vehicle (as a negative control) for 1 hr as indicated. Lysates were subjected to immunoprecipitation with anti-Smad4, 
anti-Smad2/Smad3 or anti-ERα antibody. The Smad-associated endogenous ERα was detected by immunoblot analysis. The 
expression levels of endogenous proteins were monitored by immunoblotting of total cell protein. (b) COS-1 cells were trans-
fected with HA-ERα, FLAG-Smad3 and FLAG-Smad4 expression plasmids. Cells were treated with (+) or without (-) E2 and 
TGF-β1 and subjected to sequential immunoprecipitation, DNA pull-down (DNAP), and immunoblotting. Wild-type (WT) and 
mutant (mt) biotinylated ERE oligonucleotides were used in the DNAP. The presence of HA-ERα, FLAG-Smad3 and FLAG-
Smad4 in the DNAP was detected with anti-FLAG and anti-HA antibodies.Molecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
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sion but instead stimulated estrogen-induced PS2 and C-
MYC transcription (Figure 3b). Our findings indicate that
the reduction of Smad4 protein attenuates the inhibitory
effect of TGF-β on estrogen-induced gene transcription. In
the absence of Smad4, TGF-β can regulate ERα signaling
through Smad3 and thereby might be converted from a
repressor to an activator of certain ER target gene
responses.
Abnormal Expression of Smad4 is Detected Some ERα-
positive Human Infiltrating Breast Carcinoma
Tumor cells often escape TGF-β growth inhibition
through the loss of key signaling transducers in the path-
way. Our findings suggest that Smad4 is required for TGF-
β to inhibit ERα-induced transcription, which provides
important information regarding TGF-β resistance in
breast cancer cells. It has been reported that altered expres-
sion levels or/and abnormal cellular distribution of bio-
logically active proteins are associated with some human
neoplasm [26-29]. We set to assess smad4 expression in
human breast cancer cell lines and breast cancer tissue.
While most breast cancer cell lines (e.g., MDA-MB-231)
are essentially refractory to the growth inhibition, the
MCF-7 cell line responds to TGF-β by suppression of cell
growth [30,31]. We employed both MCF-7 and MDA-MB-
231 to determine whether there is any difference in the
expression of Smad4 protein. TGF-β stimulated transloca-
tion of Smad2/3 with Smad4 into the nucleus of MCF-7
cells (Figure 4a). In the MDA-MB-231 cells, however,
Smad4 did not translocate into the nucleus with Smad2/3
in response to TGF-β stimulation (Figure 4b). These data
suggest that cytoplamic retaining of Smad4 upon TGF-β
stimulation contributes to the resistance of MDA-MB-231
to TGF-β growth inhibition. We then examined Smad4
expression in benign human breast and ERα-positive
infiltrating ductal carcinoma tissue. Smad4 was strongly
expressed in both cytoplasm and nucleus of benign breast
ductal epithelial cells from 4 individuals (Figure 4c). In
contrast, Smad4 are weekly expressed and largely
restricted in the cytoplasm of cancer cells from 8 of 12
cases with infiltrating ductal carcinoma (Figure 4d). The
variable cytoplasmic and nuclear expression of Smad4
was detected in the remaining 4 cases. To further investi-
gate the significance of Smad4 expression in breast cancer,
we examined the specimen with both benign ductal epi-
thelial and cancer cells. As shown in Figure 4e-g, the resid-
ual benign ductal epithelial cells surrounded by
infiltrating ductal carcinoma highly expressed Smad4 in
both cytoplasm and nucleus, while the expression of
Smad4 was markedly decreased and largely restricted to
cytoplasm in ERα-positive infiltrating ductal carcinoma.
These results demonstrate that the reduced expression and
abnormal cytoplasmic retaining of Smad4 protein are
present in some of ERα-positive infiltrating breast ductal
carcinoma. The data also clearly indicate a dynamic
change of Smad4 expression from benign breast ductal tis-
sue to infiltrating ductal carcinoma.
Smad4 is essential for the inhibitory effect of TGF-β in ERα-mediated transcriptional activation Figure 3
Smad4 is essential for the inhibitory effect of TGF-β in ERα-mediated transcriptional activation. (a) RNAi was 
performed in MCF-7 cells using Smad4 siRNA (see materials and methods). (b) MCF-7 cells were transfected with either 
siRNA targeting Smad4 or scrambled siRNA (as a control). Sixty hours after transfection, the cells were treated with (+) or 
without (-) E2 or TGF-β for 6 hrs. Total RNA was isolated and the mRNA levels of PS2 and C-MYC were quantitated by RT-
PCR.
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Expression of Smad4 in breast cancer cell lines and ERα-positive infiltrating beast carcinoma Figure 4
Expression of Smad4 in breast cancer cell lines and ERα-positive infiltrating beast carcinoma. (a and b) MCF-7 
and MDA-MB-231 cells were treated with TGF-β for 1 hr and then subjected to immunofluorescence analysis with anti-Smad2/
3 and anti-Smad4 antibodies to localize endogenous Smad2/3 and Smad4. Nuclei were visualized by DNA staining with DAPI. 
(c-g) Immunohistochemical staining of Smad4 in human breast tissue: (c) Benign breast ductal epithelial (1000×). (d) ERα-posi-
tive infiltrating breast carcinoma (1000×). (e) Residual benign ductal epithelial (arrow) and surrounding ERα-positive infiltrating 
breast carcinoma (200×). (f) Residual benign breast ductal epithelial in panel e (1000×). (g) Surrounding infiltrating breast carci-
noma in panel e (1000×).Molecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
Page 9 of 11
(page number not for citation purposes)
Discussion
Previous investigations have demonstrated that ER status
is a very important factor in the management of breast
cancer, and that suppression of ER mitogenic activity is a
viable strategy for treatment and prevention of breast can-
cer. TGF-β is a natural negative growth regulator of epithe-
lial cells during both development and tumorigenesis of
the mammary gland. Most breast carcinomas are refrac-
tory to the suppressive effect of TGF-β with elevated TGF-
β expression, suggesting an important role of TGF-β in
breast cancer tumorigenesis.
In previous studies, we have demonstrated that Smad4
can act as a transcriptional corepressor for ERα [21].
Smad3, on the other hand, has been shown to act as a
coactivator for ERα [19]. Since TGF-β activation leads to
the formation of an active Smad3/4 complex which
directly binds to the promoter of many TGF-β responsive
genes, it is conceivable that the Smad3/4 complex, rather
than Smad3 or Smad4 alone, plays a major role in the
crosstalk between TGF-β and estrogen. Our data clearly
indicate that the Smad3/4 complex plays the same role as
Smad4 alone, i.e., inhibiting ERα-mediated gene tran-
scription. This observation is not surprising since TGF-β
treatment alone suppresses estrogen-induced ER target
gene expression. However, it adds to the complexity of the
question why Smad3 and Smad4 act in opposite ways in
the regulation of estrogen signaling, while they have the
same effect on TGF-β signaling. One possible explanation
is that, in the context of ERα-mediated transcription,
Smad3 and Smad4 per se may recruit functionally different
cofactors such as histone acetylases and histone deacety-
lases. The protein complex(es) recruited by Smad3 or
Smad4 might determine the role of Smad3 or Smad4 as a
transcriptional cofactor in estrogen signaling. In breast
epithelial cells that have intact TGF-β/Smad and estrogen
signaling networks, the "net effect" of TGF-β may be deter-
mined by the protein complex that incorporated both
Smad3 and Smad4. In breast carcinoma cells that lack one
component of the Smad3/4 complex, Smad3 or Smad4
may act as a coactivator or corepressor for ERα that con-
fers a TGF-β activating or suppressing signal on the estro-
gen signaling pathway. The high frequency of Smad4
mutations in human tumors [32-35] suggests a role for
Smad4 as a tumor suppressor independent of TGF-β sign-
aling. Smad4 mutations in breast carcinoma have also
been reported [36,37]. In addition, the work on Smad4
conditional knockout mice also indicates that Smad4 is
required for the suppression function of TGF-β in the pro-
liferation of mammary epithelial cells [38].
We have shown that, in the presence of Smad4, TGF-β
inhibits ERα-mediated transcriptional activity. A decrease
in Smad4 expression partially or completely abrogates
TGF-β suppression of ERα-target genes, and TGF-β can
further activate ER-target genes since Smad3 acts as a tran-
scriptional coactivator for ERα (Figure 1a). It seems that
TGF-β can regulate ERα estrogenic transcriptional activity
in both a negative and positive manner, and apparently,
that the absence of Smad4 can switch TGF-β from a sup-
pressor to an activator of ER signaling. TGF-β dual regula-
tion of ERα transcriptional activity may also explain the
biphasic effect in tumors: suppression of tumor growth at
the early stages and promotion of tumor spreading during
the later stages. Further investigations are needed to iden-
tify the target genes that are specifically regulated by R-
Smads and/or Smad4, especially in the context of tumor
cells. Hopefully, the results from future studies will lead to
a better understanding of the dual role of TGF-β in cancer
development.
Loss of TGF-β inhibition can be due to mutations or dele-
tions of TGF-β signaling components. Indeed, mutations
of TGF-β receptor or Smads-encoding genes have been
reported in different forms of cancers, such as colon can-
cer and pancreatic cancer. Abnormal expression level and
cellular distribution of biologically active proteins have
been implicated in the tumorigenesis. Aberrant cytoplas-
mic localization of nucleophosmin in primary acute mye-
loid leukemia has been implicated in disrupting ARF-
MDM2-p53 signal pathway and contributed to leukemo-
genesis [39,40]. Significant reduced expression of Smad4
protein was found in some human carcinoma including
breast cancer [41-44]. Our data demonstrate that, in TGF-
β-treated MDA-MB-231 cells, Smad4 failed to translocate
into the nucleus with Smad2/3, therefore losing the func-
tion of Smad4 as a repressor in the nucleus and probably
contributing to decreased growth inhibition of TGF-β in
this cell line. In addition, the expression of Smad4 are
decreased and largely restricted in the cytoplasm of some
of ERα-positive infiltrating human breast cancer cells in
contrast to the benign breast tissue in which Smad4 was
strongly expressed in both cytoplasm and nucleus of duc-
tal epithelial cells. Moreover, the marked difference of
Smad4 expression is noted between carcinoma cells and
surrounding residual normal ductal tissue from same
specimen (Fig. 4e-g). These data indicate that the dysregu-
lation of Smad4 protein expression may play a role in the
development and progression of ERα-positive breast car-
cinoma. The fact that aberrant expression of Smad4 is
only seen some of ERα-positive infiltrating breast cancer
is consistent with the heterogeneity of human breast car-
cinoma in biological features, development and progres-
sion, and therapy response. It is likely that in an ERα-
positive breast carcinoma with aberrant expression of
Smad4, TGF-β not only is unable to inhibit tumor growth,
but also promote tumor progression through enhancing
the estrogen-ERα mediated cell proliferation. The mecha-
nism for dysregulation of Smad4 expression in ERα-posi-
tive infiltrating breast cancer is still unknown. It could beMolecular Cancer 2009, 8:111 http://www.molecular-cancer.com/content/8/1/111
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due to mutations or deletion of Smad4, or aberrant
expression of certain oncoproteins. Our findings may pro-
vide a basic mechanism to explain the lack of TGF-β
responsiveness and anti-estrogen-dependent growth inhi-
bition in some of ERα-positive infiltrating breast carci-
noma, support an idea of both tumor suppressing and
enhancing effects of TGF-β in the development and/or
progression of breast cancer, and open a path to further
investigate the cause of aberrant expression of Smad4 in
ERα-positive infiltrating breast carcinoma.
Conclusion
We have shown that TGF-β can regulate ERα estrogenic
transcriptional activity in both negative and positive man-
ners. Smad4 is essential for TGF-β-mediated inhibition of
ERα estrogenic transcription activity, and the inhibition of
Smad4 expression switches TGF-β from a repressor to an
activator for ERα transactivation in breast cancer cells. We
have demonstrated that down-regulation and relatively
increased cytoplasmic localization of Smad4 were associ-
a t e d  w i t h  s o m e  E R α-positive infiltrating human breast
carcinoma. These results suggest that aberrant expression
of Smad4 or disruption of Smad4 activity be one of mech-
anisms for loss of TGF-β negative regulation on ERα tran-
scriptional activity in breast cancer.
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